Hong Kong
· Delayed Price · Currency is HKD Lee's Pharmaceutical Holdings Company Description
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China.
It focuses on various disease areas, such as cardiovascular, woman’s health, paediatrics, rare diseases, oncology, dermatology, and obstetrics.
It operates through Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Nadroparin Calcium injection and Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Socazolimab Injection for Recurrent or metastatic cervical cancer; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders; Apremilast Tablets for Plaque psoriasis; and Azilsartan Tablets for Hypertension.
The Licensed-In Products segment offers Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Ferplex to treat iron deficiency anemia.
This segment also offers Intrarosa for vulvovaginal atrophy; Adasuve for agitation associated with schizophrenia or bipolar I disorder in adults; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin’s disease; Lutrate for Prostate cancer; Nitric Oxide for Inhalation for Hypoxic respiratory failure associated with pulmonary hypertension; Omacor to treat Omega-3-acid ethyl esters; Zanidip for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics.
The company was founded in 1994 and is headquartered in Shatin, Hong Kong.
| Country | Cayman Islands |
| Founded | 1994 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,022 |
Contact Details
Address: Building 20E Shatin Hong Kong | |
| Phone | 852 2314 1282 |
| Website | leespharm.com |
Stock Details
| Ticker Symbol | 0950 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | HKD |
| ISIN Number | KYG5438W1116 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Siu Fong Lee | Chairman and Compliance Officer |
| Dr. Xiaoyi Li Ph.D. | Founder, Senior Adviser and Non-Executive Director |
| Wanee Leelalertsuphakun | MD, Chief Marketing and Sales Officer and Executive Director |
| Yiu Ming Chow | Group Chief Financial Officer and Company Secretary |
| Yueshen Chen | Director of Administration in China |
| Tsui Victor Kailok M.Sc., P.E. | Group Chief Manufacturing Officer |
| Yuanjue Sun | Chief Medical Officer |
| Zhongyu Jiao | Group Deputy GM and GM of the Risk Control Centre |